LONDON, March 11, 2015 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Threshold Pharmaceuticals
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Highlights of the analysis on Threshold Pharmaceuticals by Edison's pharma & biotech analysts Dr Philippa Gardner, Maxim Jacobs, and Dr Mick Cooper are as follows:
Threshold Pharmaceuticals is a US oncology company focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Phase III for soft tissue sarcoma (STS) and pancreatic cancer and earlier trials in multiple other cancers, and is partnered with Merck KGaA.
Our Threshold valuation is $949m or $13.4/share based on an NPV analysis, including net cash and evofosfamide in a variety of indications, risk-adjusted to reflect the current stage of development. This includes our base-case market share assumptions until there is more clarity on the magnitude of evofosfamide's benefit. Pro forma $86.8m net cash, post the $30m fund-raise, should be sufficient to fund operations into 2017, beyond Phase III data readouts.
To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do'sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Formore informationplease contact:
Dr Philippa Gardner, Edison Investment Research, +44(0)20-3681-2521
Maxim Jacobs, CFA, Edison Investment Research, +1-646-653-7027
Dr Mick Cooper, Edison Investment Research, +44(0)20-3077-5734
healthcare@edisongroup.com
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn: http://www.linkedin.com/company/edison-investment-research
Twitter: http://www.twitter.com/Edison_Inv_Res
YouTube: http://www.youtube.com/edisonitv
